- Home
- IFRX vs BKTI Comparison
IFRX vs BKTI Comparison
Compare IFRX & BKTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- BKTI
- Stock Information
- Founded
- IFRX 2007
- BKTI 1997
- Country
- IFRX Germany
- BKTI United States
- Employees
- IFRX N/A
- BKTI N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- BKTI Radio And Television Broadcasting And Communications Equipment
- Sector
- IFRX Health Care
- BKTI Technology
- Exchange
- IFRX Nasdaq
- BKTI Nasdaq
- Market Cap
- IFRX 143.7M
- BKTI 124.4M
- IPO Year
- IFRX 2017
- BKTI N/A
- Fundamental
- Price
- IFRX $2.47
- BKTI $32.18
- Analyst Decision
- IFRX Strong Buy
- BKTI
- Analyst Count
- IFRX 1
- BKTI 0
- Target Price
- IFRX $8.00
- BKTI N/A
- AVG Volume (30 Days)
- IFRX 174.5K
- BKTI 31.9K
- Earning Date
- IFRX 11-08-2024
- BKTI 03-13-2025
- Dividend Yield
- IFRX N/A
- BKTI N/A
- EPS Growth
- IFRX N/A
- BKTI N/A
- EPS
- IFRX N/A
- BKTI 1.39
- Revenue
- IFRX $187,930.00
- BKTI $74,972,000.00
- Revenue This Year
- IFRX $392.79
- BKTI $10.13
- Revenue Next Year
- IFRX $156.76
- BKTI $25.00
- P/E Ratio
- IFRX N/A
- BKTI $24.97
- Revenue Growth
- IFRX 177.12
- BKTI N/A
- 52 Week Low
- IFRX $1.17
- BKTI $11.06
- 52 Week High
- IFRX $2.82
- BKTI $38.70
- Technical
- Relative Strength Index (RSI)
- IFRX 53.59
- BKTI 45.84
- Support Level
- IFRX $2.16
- BKTI $31.65
- Resistance Level
- IFRX $2.65
- BKTI $35.00
- Average True Range (ATR)
- IFRX 0.23
- BKTI 2.03
- MACD
- IFRX -0.01
- BKTI -0.19
- Stochastic Oscillator
- IFRX 52.54
- BKTI 39.45
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About BKTI BK Technologies Corporation
BK Technologies Corp a holding company, operates primarily through its subsidiary, BK Technologies, Inc., specializing in designing, manufacturing, and marketing wireless communications equipment. Its Radio business unit offers two-way land mobile radios (LMRs) serving government and public safety markets, as well as industrial and commercial enterprises. The SaaS business unit focuses on public safety smartphone applications, enhancing first responders' safety and efficiency. The BKRplay application, tethered to BK radios, amplifies user capabilities, expanding the reach of their radio sales. Its product portfolio consists of two-way land mobile radios, handheld radios, radios installed in vehicles.